Use of Midodrine in Post-cardiopulmonary Bypass Vasoplegic Syndrome Clinical Trial
Official title:
Midodrine as Novel Treatment of Post-Cardiopulmonary Bypass Vasoplegic Syndrome
| Verified date | June 2022 |
| Source | Medstar Health Research Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Vasoplegic syndrome (VS) is a common and serious complication of cardiopulmonary bypass (CPB) procedures associated with a significant increase in morbidity and mortality. VS is defined as significant hypotension, high or normal cardiac outputs, low systemic vascular resistance, low cardiac filling pressures, and vasopressor requirement despite adequate fluid resuscitation following CPB. Extensive research has been performed regarding the pathophysiologic response to CPB and risk factors associated with VS. No safe and effective preventive strategy has gained widespread use. Supportive care with intravenous (IV) vasopressors has thus been adopted as standard of care. The use of these medications, while effective in the majority of patients, generally necessitates close monitoring in an intensive care unit (ICU) setting. These patients are subject to prolonged ICU and hospital stays, as well as the potential complications of prolonged use of central venous lines (CVL) required to give these medications. Recent studies suggest midodrine, a generic oral vasopressor, may accelerate the decline in IV vasopressor requirements in select ICU patients. At our institution, the addition of midodrine to IV vasopressors for the treatment of VS has been observed to be effective in reducing IV vasopressor duration. No literature exists describing the use of midodrine in this patient population. The goal of this study is to investigate the novel use of midodrine in CPB surgery complicated by VS. Ultimately, we hope to produce literature supporting its use that may be applied on a global scale to improve patient care
| Status | Terminated |
| Enrollment | 10 |
| Est. completion date | August 8, 2018 |
| Est. primary completion date | August 8, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - post-cardiopulmonary bypass surgery - vasoplegic syndrome criteria 1. MAP < 65mmHg 2. Cardiac index>/=2.4 L/min/m^2, as determined by Swan- 3. systemic vascular resistance index </=1400 dynes s/cm^5/m^2 4. adequate fluid resuscitation as determined by treating critical care team - vasopressor requirement 1. norepinephrine 0.05-0.5 mcg/kg/min WITH/WITHOUT 2. vasopressin any dose Exclusion Criteria: - allergy to midodrine - pregnancy - midodrine or cardiac glycoside as preadmission medication - history of orthostatic hypotension, thyrotoxicosis, or pheochromocytoma - severe organic heart disease (endocarditis, untreated congenital or rheumatic heart disease) - liver failure/cirrhosis - chronic kidney disease (GFR <30mL/hr) - ventricular assist device implantation procedure, intra-aortic balloon pump placement, or heart transplantion - unresolved post-operative acute kidney injury (rise in serum creatinine by >/= 0.5mg/dl from baseline - inadequate tissue oxygenation (lactate > 2 mmol/L) - inability to take oral medications |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Medstar Health Research Institute |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Time from procedure end until discontinuation of IV vasopressors | 12 months | ||
| Secondary | Rate of decline in IV vasopressor dose | 12 months | ||
| Secondary | Time until CVL removal | 12 mothns | ||
| Secondary | ICU length of stay | 12 months | ||
| Secondary | Hospital length of stay | 12 months | ||
| Secondary | Rate of major infections/complications | 12 months | ||
| Secondary | Rate of in-hospital and 30-day mortality | 12 months |